octreotide acetate / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 141 Diseases   27 Trials   27 Trials   1501 News 


«1234567891011»
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Journal:  Peptide Receptor Radionuclide Therapy Performed Shortly After Administration of Long-Acting Octreotide. (Pubmed Central) -  Nov 8, 2023   
    Because of miscommunication in scheduling, his fourth cycle was performed only 48 hours after his last full dose of octreotide LAR. Despite this, we found that the tumoral uptake was not reduced at all, which may add to the increasing evidence on the nonnecessity of stopping somatostatin analogs before peptide receptor radionuclide therapy.
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Journal:  Clinicopathological Features of Insulinoma: A Single Tertiary Center Experience. (Pubmed Central) -  Oct 30, 2023   
    Octreotide LAR was given to 1 patient with metastatic disease and 1 patient who did not accept surgery...The 48-h fasting test period provided sufficient information for the diagnosis of insulinoma. Ga-68 DOTATATE PET/CT may be an alternative in cases where cross-sectional imaging cannot localize the pancreatic lesion.
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    New trial, Real-world evidence, Real-world effectiveness, Real-world:  Real-world Study on Adjuvant Octreotide Therapy in pNETs (clinicaltrials.gov) -  Oct 12, 2023   
    P=N/A,  N=411, Completed, 
  • ||||||||||  Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Journal, HEOR, Real-world evidence, Adherence, Real-world:  Treatment Patterns, Adherence, Persistence, and Health Care Resource Utilization in Acromegaly: A Real-World Analysis. (Pubmed Central) -  Sep 14, 2023   
    Patients with more comorbidities had more health care visits during the first year after diagnosis, suggesting increased disease burden. Real-world evidence on treatment patterns provides insights into recommendations for individualized therapy.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Journal, Metastases:  Severe hypercalcemia due to metastatic pancreatic neuroendocrine tumor: a case report. (Pubmed Central) -  Sep 8, 2023   
    Generally, survival is better; however, its treatment is challenging, and primary debulking surgery is often required. A team approach to management is important at all points.
  • ||||||||||  Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
    Trial completion date, Trial primary completion date, Metastases:  Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors (clinicaltrials.gov) -  Sep 6, 2023   
    P1,  N=14, Recruiting, 
    A team approach to management is important at all points. Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Aug 2023 --> Dec 2023
  • ||||||||||  Avastin (bevacizumab) / Roche, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Octreotide as an Effective Alternative for Managing Refractory GI Bleeding in Hereditary Hemorrhagic Telangiectasia (Exhibit Hall) -  Jul 29, 2023 - Abstract #ACG2023ACG_2532;    
    Due to the extensive nature of the angiectasias and the patient's poor surgical candidacy, he was initiated on subcutaneous octreotide 200 mg subcutaneously twice daily during hospitalization and transitioned to long-acting octreotide, 20 mg once a month for six months after discharge...Systemic therapies like bevacizumab and thalidomide have shown only moderate evidence of effectiveness...Therefore, it should be considered as a valuable option in the management of refractory GI bleeding in patients with HHT Figure: Fig 1: Clinical and endoscopic findings. 1A - angiectasias on the palate, tongue, and lips, 1B - multiple non bleeding angiectasias in the second portion of the duodenum & 1C - Capsule endoscopy showing multiple duodenal AVMs with recent bleeding
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Rectal Adenocarcinoma Mimic: A Rare Case of Metastatic Rectal Neuroendocrine Tumor (Exhibit Hall) -  Jul 29, 2023 - Abstract #ACG2023ACG_687;    
    After further oncology evaluation, long-acting octreotide acetate was initiated, and she continues close follow up...Fig 1c. Histology slide of rectal polyp 400x H&E showing uniform round nuclei with finely stippled
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Phase classification, Trial completion date, Trial primary completion date:  OCEAN: Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias (clinicaltrials.gov) -  May 18, 2023   
    P3,  N=62, Completed, 
    Unknown status --> Completed Unknown status --> Completed | Phase classification: P2/3 --> P3 | Trial completion date: Dec 2019 --> May 2023 | Trial primary completion date: Nov 2019 --> Jul 2022
  • ||||||||||  cabergoline / Generic mfg.
    Novel Approach To Management of Acromegaly with De Novo Oral Octreotide Or Combination Therapy with Cabergoline: A Case Series (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_905;    
    First line medical therapy consists of first-generation injectable somatostatin receptor ligands (SRL) (octreotide LAR, lanreotide autogel)...If IGF-1 levels do not normalize, pasireotide or pegvisomant can be tried...The dose was increased to 80 mg daily are lab results are pending. These are the first two published cases describing a novel approach to treating acromegaly in which patients were found to have a biochemical response to de novo oral octreotide either alone or combined with cabergoline.
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Title: Adult-onset Hyperinsulinemic Hypoglycemia due to an Activating Mutation in Glucokinase (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_703;    
    Change to multiple small meals, addition of cornstarch to diet, continuous blood glucose monitoring (CGM), diazoxide (70 mg oral, three times a day), and monthly octreotide LAR (30 mg) has allowed the patient to avoid hypoglycemia... Our study highlights that in adults with non-insulinoma pancreatogenous hypoglycemia, genetic causes of HH should be considered in the differential diagnosis.
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Atypical presentation of Birt-Hogg-Dub (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_270;    
    Genetic testing will aid in diagnosing a germline mutation in the FLCN gene. The association between thyroid cancer and BHDS has been reported previously; however, paraganglioma as a spectrum of BHDS has not been published.
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Review, Journal:  Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice from NET specialists. (Pubmed Central) -  May 7, 2023   
    The questions regarded the use of long-acting octreotide and lanreotide in the following settings: functioning and non-functioning NET refractory to label dose, first-line metastatic pulmonary NET, combination with other therapy with an antiproliferative intent, maintenance in NET responding to other therapies, adjuvant treatment, Ki-67-related cut-off, somatostatin receptor imaging, safety, and feasibility...Mention of such specific issues by the main European guidelines (ENETS, European Neuroendocrine Tumor Society, and ESMO, European Society for Medical Oncology) was explored and their position reported. However, different clinical decisions on single patients could be made if the case is carefully discussed within a NET-dedicated multidisciplinary team.
  • ||||||||||  Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide (clinicaltrials.gov) -  Apr 12, 2023   
    P4,  N=53, Completed, 
    Paltusotine was well tolerated with a safety profile consistent with other SRLs. Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Apr 2023 | Trial primary completion date: Sep 2024 --> Apr 2023
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Journal:  The effect of long-acting somatostatin analogues on the uptake of [Lu]Lu-HA-DOTATATE. (Pubmed Central) -  Mar 24, 2023   
    Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Apr 2023 | Trial primary completion date: Sep 2024 --> Apr 2023 Long-acting octreotide and lanreotide do not interfere with the uptake of [Lu]Lu-HA-DOTATATE in tumour lesions 24
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Thoracic neuroendocrine tumors: Experience in a third level hospital in Mexico (Exhibition and Poster area) -  Feb 14, 2023 - Abstract #ELCC2023ELCC_531;    
    Results 41 patients were evaluated; those with typical carcinoid (n?=?15) and atypical carcinoid diagnosis (n?=?21) were treated with first-line SSAs: 23 patients with octreotide LAR and 11 with lanreotide. Subjects with LCNEC diagnosis (n?=?6) were treated with first-line platinum/etoposide chemotherapy during 4
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Trial termination:  Acromegaly Combination Treatment Study (clinicaltrials.gov) -  Jan 4, 2023   
    P=N/A,  N=76, Terminated, 
    Completed --> Terminated; Review of the 12-month data showed patients who deviated from protocol with full IRB monitoring and reporting could not be optimally analyzed. Reopening the study for new enrollment is not feasible and the study was terminated with IRB approval.
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Review, Journal:  The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next? (Pubmed Central) -  Nov 18, 2022   
    A second pivotal study COMPETE is currently in progress, comparing no carrier-added (n.c.a.) Lu-177-DOTATOC to the m-TOR inhibitor Everolimus in both GE-NETs and PNETs...Antagonists have a higher tumor binding to receptors than agonists, opening up the potential indications for SSTR2 targeting to tumors which have a relatively lower expression of SSTR2 compared to NET such as small cell lung cancer, hepatocellular carcinoma and breast cancer. In addition to Lu-177, radioisotopes with different radiation properties such as Tb-161 and the α-emitter Ac-225 are being developed which have the potential to improve treatment efficacy across the range of G1 to G3 NETs.
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    McCune Albright Syndrome in children- Case series from a Tertiary Care Centre- Sri Lanka (Rome, Italy) -  Nov 13, 2022 - Abstract #ESPE2022ESPE_1659;    
    He continued to have high IGF-1 and GH level needing long acting octreotide at 11 years...Other endocrine functions are normal at 5 years. MAS has various different presentations therefore it's important to follow them up regularly and actively look for developing endocrinopathies.
  • ||||||||||  Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Real World Analysis of Long-Acting Somatostatin Analog (LA-SSA) Treatment and Dose Escalation Among Patients with Neuroendocrine Tumors (NET) () -  Nov 8, 2022 - Abstract #NANETS2022NANETS_178;    
    Amongst patients whose initial treatment ended during follow-up (90 LAN and 274 octreotide LAR patients), fewer LAN patients transitioned to the other LA-SSA compared to octreotide LAR (19% (n=17) vs. 34% (n=92), p-value=0.008). CONCLUSIONS Compared with octreotide LAR patients, LAN patients were more likely to remain on their initial LA-SSA treatment longer as well as on their starting dose without dose escalation, and less likely to use rescue treatment.
  • ||||||||||  Solucin (177Lu-edotreotide) / ITM Isotopen Technologien Munchen, Lutathera (lutetium Lu 177 dotatate) / Novartis, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Journal:  A rare case of poorly differentiated mixed neuroendocrine-nonneuroendocrine tumor of the caecum with long term survival: A case report. (Pubmed Central) -  Oct 28, 2022   
    The patient received somatostatin analogue therapy followed by long-acting release octreotide analogue therapy (30 mg/month) showing a partial improvement of relevant biomarkers. Two years later, carcinoid syndrome symptoms reappeared and due to the tumors expression of somatostatin receptors the patient received peptide receptor radionuclide therapy with 177Lu-DOTATATE that resulted in both clinical and biochemical improvements.
  • ||||||||||  Lutathera (lutetium Lu 177 dotatate) / Novartis
    Enrollment closed, Trial completion date, Metastases:  NETTER-2: Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (clinicaltrials.gov) -  Oct 5, 2022   
    P3,  N=222, Active, not recruiting, 
    Two years later, carcinoid syndrome symptoms reappeared and due to the tumors expression of somatostatin receptors the patient received peptide receptor radionuclide therapy with 177Lu-DOTATATE that resulted in both clinical and biochemical improvements. Recruiting --> Active, not recruiting | Trial completion date: Oct 2027 --> Jul 2027